Policy / Pricing Most patients “won’t see benefit” with Alzheimer’s drugs PharmaphorumA review of clinical data on amyloid-targeting Alzheimer's therapies has found absent or trivial efficacy, but is facing pushback from some experts.Policy / PricingNeuroscienceRead full story pharminent April 16, 2026 (Last updated: April 16, 2026) Pharmaphorum A review of clinical data on amyloid-targeting Alzheimer’s therapies has found absent or trivial efficacy, but is facing pushback from some experts. Policy / PricingNeuroscienceRead full story Post navigation Previous: Terremoto wins $108m in Series C to drive cancer and rare disease programmesNext: Beeline raises $300m for BMS drugs, and other biofinancings Related Stories Policy / Pricing Mid-cap biotechs join Trump’s latest round of drug pricing deals pharminent September 1, 2026 Policy / Pricing MFN sparks defiance from Europe’s larger nations, uncertainty among smaller ones pharminent August 27, 2026 Policy / Pricing MFN affecting Swiss medicines access, says Interpharma pharminent August 13, 2026